Monaco Journal - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
CMSC 0.58% 22.29 $
SCS 1.71% 9.92 $
CMSD 0.59% 22.423 $
BTI 0.12% 42.56 $
BCE -1.07% 21.985 $
BCC 2.72% 95.94 $
GSK 1.07% 37.43 $
NGG 0.84% 72.315 $
RBGPF -0.71% 63 $
RIO 2.51% 61.75 $
RYCEF 3.46% 9.84 $
AZN 1.42% 69.5 $
JRI 1.34% 12.66 $
BP 1.46% 29.025 $
VOD -0.05% 9.295 $
RELX 0.99% 53.225 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

A.Galli--MJ